Ÿnsect collapses after raising over $600 million

French insect farming startup Ÿnsect has been placed into judicial liquidation — essentially bankruptcy — for insolvency. The decision marks a sudden end for a company that once attracted high-profile backing, including from Robert Downey Jr. and his FootPrint Coalition, alongside impact-focused investors like Astanor Ventures and the French public investment bank Bpifrance. In total, the company raised over $600 million in funding. Judicial liquidation is a legal process for bankruptcy and winding down a company that can no longer meet its financial obligations.

The startup struggled to balance its massive industrial ambitions with commercial reality. While Ÿnsect initially targeted animal feed and human food—acquiring Dutch mealworm developer Protifarm in 2021—it struggled to generate meaningful sales. Although many Westerners feel an aversion to eating insects, human food was never the company’s primary focus. Instead, the company’s financial performance highlights the scale of the mismatch:

• Peak revenue from its main entity reached €17.8 million (approximately $21 million) in 2021, a figure reportedly inflated by internal transfers.
• Net loss reached €79.7 million ($94 million) in 2023.

In response to these losses, Ÿnsect attempted to pivot toward higher-margin pet food. Former CEO Antoine Hubert noted that inflation on energy, raw materials, capital, and debt meant the company could not afford to invest heavily in animal feed, its least remunerative market. However, the shift came too late. The company had already committed hundreds of millions to build Ÿnfarm, a “giga-factory” in Northern France. A giga-factory is a massive, capital-intensive production facility. Ÿnsect built this facility before proving its business model or unit economics.

The collapse has triggered broader discussions about the industrial ecosystem in Europe. Joe Haslam, a professor who teaches a course on Scaling Up in the MBA Program at IE Business School, argues that the startup’s struggles stem from a mismatch between industrial ambition, capital markets, and timing. He views the company as a prime example of the region’s “scaling gap”—defined as the difficulty of transitioning from pilot projects to industrial-scale operations. “Ÿnsect is a case study in Europe’s scaling gap. We fund moonshots. We underfund factories. We celebrate pilots. We abandon industrialization. See Northvolt [a struggling Swedish battery maker], Volocopter [a German air taxi startup], and Lilium [a failed German flying taxi company],” Haslam said.

The failure does not mean the entire insect farming sector is unviable. Competitor Innovafeed is reportedly holding up better by starting with a smaller production site. Meanwhile, Ÿnsect’s current CEO, Emmanuel Pinto, stated that the company’s remaining assets are now available, hoping its expertise will still contribute to Europe’s protein independence.

Why it matters

Ÿnsect’s collapse illustrates the scaling gap in Europe, where startups struggle to bridge the divide between initial funding and industrial-scale production. The failure highlights the severe risks of building capital-intensive giga-factories before proving unit economics and establishing clear market demand.